# Charles River Laboratories (CRL) Forecast Calculator

Interactive five-year financial forecast and DCF for Charles River Laboratories. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/charles-river-laboratories/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 2621226000 | 340422000 | 549246000 | 252019000 |
| 2022 | 2923933000 | 380015000 | 667653000 | 364304000 |
| 2023 | 3540160000 | 532027000 | 855402000 | 390982000 |
| 2024 | 3976060000 | 294907000 | 954845000 | 486226000 |
| 2025 | 4129409000 | 365370000 | 931385000 | 474624000 |

## Frequently asked questions

### What does Charles River Laboratories do?

Charles River Laboratories (CRL) is a leading early-stage contract research organization (CRO) that provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. They help accelerate research and drug development efforts through their Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions segments.

### What are the main revenue drivers for Charles River Laboratories?

Charles River Laboratories' revenue is primarily driven by its Discovery and Safety Assessment services, which account for approximately 60% of its revenue. Other significant drivers include Research Models and Services (21%) and Manufacturing Solutions (19%), all supporting the drug development lifecycle.

### What is Charles River Laboratories' typical capital expenditure as a percentage of revenue?

Charles River Laboratories typically allocates 5.0% to 7.0% of its revenue to capital expenditure. This capex is split approximately 40% for maintenance and 60% for growth, funding capacity expansion for animal housing and safety assessment labs.

### How does Charles River Laboratories' working capital profile impact its financial model?

Charles River Laboratories has a positive net working capital profile, typically ranging from 5-8% of revenue, which is essential for funding live biological assets like NHP inventory and lab supplies. This positive working capital requirement is an important input for cash flow projections in a financial model.

### Can I download a financial model for Charles River Laboratories (CRL)?

Yes, a downloadable Excel financial model is available for Charles River Laboratories (CRL). This model forecasts consolidated cash flows and earnings from FY2026 to FY2030 to determine equity valuation.

### Why does Charles River Laboratories have a high proportion of goodwill and intangibles on its balance sheet?

Charles River Laboratories' balance sheet features a significant proportion of goodwill and intangibles, making up about 60-65% of total assets. This is primarily due to the company's historical strategy of serial acquisitions, though recent impairments have led to a decrease in this percentage.